List of Excipients in Branded Drug METARAMINOL BITARTRATE

« Back to Dashboard

Generic Drugs Containing METARAMINOL BITARTRATE

Company	Ingredient	NDC	Excipient
Azurity Pharmaceuticals Inc	metaraminol bitartrate	24338-090	METHYLPARABEN
Azurity Pharmaceuticals Inc	metaraminol bitartrate	24338-090	PROPYLPARABEN
Azurity Pharmaceuticals Inc	metaraminol bitartrate	24338-090	SODIUM CHLORIDE
Azurity Pharmaceuticals Inc	metaraminol bitartrate	24338-090	SODIUM METABISULFITE

What are the Most Frequently-Used Excipients in METARAMINOL BITARTRATE?

# Of NDCs	Excipient
1	METHYLPARABEN
1	PROPYLPARABEN
1	SODIUM CHLORIDE
1	SODIUM METABISULFITE

Metaraminol Bitartrate Excipient Strategy and Commercial Opportunities

Last updated: October 8, 2026

Metaraminol bitartrate is an established sympathomimetic vasopressor used primarily for short-term treatment of hypotension in anesthesia and acute-care settings. Its commercial opportunity is concentrated in sterile dosage-form execution rather than novel-molecule exclusivity. The strongest product concepts are preservative-free, ready-to-use presentations with controlled pH, low particulate burden, validated container compatibility, and clear dose-conversion labeling.

What is metaraminol bitartrate used for?

Metaraminol is a direct and indirect sympathomimetic that increases vascular tone and blood pressure. Injectable products are used for hypotension associated with anesthesia, spinal or epidural procedures, and selected acute-care situations. The drug is administered intravenously or intramuscularly, with intravenous use requiring dilution or a concentration appropriate to the clinical protocol.[1]

The principal formulation challenge is not dissolution. Metaraminol bitartrate is water-soluble as an ionic salt. The commercial risks are oxidation, pH drift, adsorption or interaction with the container system, particulate formation, dose-concentration confusion, and inconsistent stability after dilution.

What excipients are used in metaraminol bitartrate injections?

A commercially efficient formulation should begin with a minimal-excipient, aqueous system:

Formulation element	Commercial function	Recommended strategy
Water for Injection	Primary vehicle	Use compendial-quality WFI with validated bioburden and endotoxin control
Sodium chloride or another tonicity agent	Osmolality adjustment	Select the lowest level that supports acceptable osmolality and stability
Hydrochloric acid or sodium hydroxide	pH adjustment	Use narrow, validated pH control rather than a high-capacity buffer
Nitrogen overlay	Oxygen reduction	Evaluate for oxidation-sensitive formulations in vials and ampoules
Chelating agent	Trace-metal control	Consider only if forced-degradation data show a meaningful benefit
Antioxidant	Oxidation control	Use only when necessary because of injectable safety, labeling, and compatibility implications
Preservative	Multidose microbiological protection	Avoid in single-dose intravenous products unless a clear product strategy requires multidose use

The exact inactive-ingredient profile depends on the manufacturer and jurisdiction. Product labels and regulatory databases should control the final formulation specification.[1,2]

Why a minimal-excipient formulation is preferable

Metaraminol bitartrate is generally suited to a simple aqueous injectable formulation. A short excipient list reduces:

• Intravenous tolerability concerns
• Regulatory review complexity
• Extractables and leachables risk
• Compatibility failures with infusion systems
• Labeling burden
• Manufacturing variability
• Risk of precipitation after dilution

A simple formulation also supports multiple presentations from one bulk solution, including vials, ampoules, prefilled syringes, and infusion bags.

What pH range is suitable for metaraminol bitartrate?

The target pH should be established through degradation and compatibility studies rather than copied from a related sympathomimetic. An acidic formulation is commercially plausible because the bitartrate salt is more likely to remain soluble and chemically controlled at lower pH. The final range must balance:

1. Chemical stability.
2. Visual clarity.
3. Container compatibility.
4. Injection-site tolerability.
5. Compatibility with dilution fluids.
6. Stability after opening or dilution.

A low-capacity pH-adjustment system is usually preferable to a strong phosphate or citrate buffer unless the data show that buffering is necessary. Excessive buffer capacity can increase compatibility problems after dilution and may complicate administration through small-bore lines.

Should metaraminol injections contain antioxidants?

An antioxidant should not be added automatically. The development sequence should be:

1. Establish degradation pathways under heat, light, oxygen, and metal-ion stress.
2. Determine whether oxygen exclusion and container selection control the observed degradation.
3. Evaluate chelation only if trace-metal catalysis is demonstrated.
4. Add a reducing agent only if it provides a clear stability advantage without creating new safety or analytical problems.

Sulfite-based antioxidants may create labeling and hypersensitivity considerations for parenteral products. They can also complicate impurity profiling and compatibility assessment. A nitrogen headspace, low-oxygen manufacturing process, light-protective packaging, and an appropriate pH may provide a cleaner commercial solution.

Which metaraminol bitartrate dosage forms have the strongest commercial potential?

Ready-to-use prefilled syringes

A ready-to-use syringe is the highest-value formulation opportunity. It can reduce bedside preparation, dilution errors, and medication-selection risk during anesthesia or emergency care.

A commercially attractive presentation would include:

• Single-dose, preservative-free packaging
• Standardized concentration
• Clear expression of metaraminol base and bitartrate salt
• Tamper-evident packaging
• Luer-lock compatibility
• Extended in-use stability
• Barcoded unit-dose labeling
• Protection from light where required

The product should avoid a concentration that forces repeated mental conversion between salt mass and active-base equivalent. Labeling should display the clinically relevant dose prominently.

Ready-to-use infusion bags

Low-concentration infusion bags could target operating rooms, intensive-care units, and emergency departments. The main development issue is stability after dilution in commonly used infusion vehicles, including sodium chloride and dextrose solutions.

The development program should assess:

• Chemical stability over the proposed shelf life
• Stability after spiking or transfer
• Compatibility with polyvinyl chloride and polyolefin bags
• Adsorption to tubing
• Pump-related shear and air exposure
• Particulate generation
• Light exposure
• Microbiological risk after connection

Infusion bags have a larger commercial opportunity than ampoules where hospitals are actively reducing bedside compounding. Their disadvantage is higher logistics cost and greater container-system complexity.

Single-dose vials

Single-dose vials remain the lowest-complexity route for a manufacturer. They support flexible dilution and are easier to adapt to multiple markets. The commercial weakness is that they shift preparation and dosing responsibility to the healthcare provider.

Vial products should be evaluated in both concentrated and diluted strengths. A concentrated vial may serve hospitals that maintain pharmacy-controlled compounding. A lower-strength vial can reduce preparation steps in procedural areas.

Ampoules

Ampoules offer established sterile packaging but have operational disadvantages. Glass breakage, particulate risk, transfer steps, and incompatibility with automated medication systems can limit hospital preference. Ampoules may remain commercially relevant in markets where they are the established presentation, but they are less differentiated than syringes.

What manufacturing and excipient controls are required?

Metaraminol bitartrate injection should be developed as a sterile drug product under current good manufacturing practice requirements. FDA regulations require controls for components, process validation, laboratory testing, container-closure systems, and sterile manufacturing operations.[3]

Critical process controls include:

• Control of incoming metaraminol bitartrate identity, assay, water content, and related substances.
• Control of solution pH and osmolality.
• Low-bioburden compounding before sterile filtration.
• Validated sterilizing filtration, where applicable.
• Aseptic filling and closure.
• Container-closure integrity testing.
• Visible and subvisible particulate testing.
• Endotoxin testing.
• Light-stability testing.
• Stability testing in the proposed commercial package.
• In-use and dilution stability studies.

The active pharmaceutical ingredient should be evaluated for residual solvents, elemental impurities, polymorphic or solid-state variation, and degradation during storage. Even when the finished product is an aqueous solution, API variability can affect pH, color, impurity growth, and filter performance.

What container systems are suitable?

The most commercially relevant options are:

Container	Advantages	Principal risks
Type I glass vial	Established injectable platform; strong barrier	Delamination, breakage, stopper interaction
Glass ampoule	Low closure complexity; established use	Breakage, particulate generation, transfer burden
Polymer vial	Reduced breakage; automation potential	Permeation, adsorption, extractables
Prefilled glass syringe	Administration efficiency; unit-dose workflow	Silicone oil, plunger interaction, syringe stability
Plastic infusion bag	Ready-to-use dosing; large-volume delivery	Sorption, leachables, oxygen permeability

Container selection should be based on extractables and leachables, oxygen transmission, light protection, adsorption, and closure integrity. A formulation that is stable in glass is not automatically stable in a polymer syringe or infusion bag.

How can excipients create commercial differentiation?

Excipient selection can support four defensible product attributes:

1. Longer shelf life

A formulation using controlled pH, low oxygen exposure, and a compatible container may achieve a longer shelf life than an incumbent product. The commercial value is highest if the product can be stored under standard room-temperature conditions and does not require special light protection or refrigeration.

2. Longer in-use stability

An infusion-ready presentation can gain hospital preference if supported by data after dilution, line connection, and simulated administration. In-use claims must be based on validated chemical and microbiological studies.

3. Lower preparation burden

A prefilled syringe or ready-to-use bag can reduce manipulation, dilution, and labeling steps. This is particularly relevant in anesthesia, where treatment decisions occur under time pressure.

4. Compatibility with automated systems

A unit-dose syringe with standardized concentration, barcoding, and common connector compatibility can support pharmacy automation and electronic medication administration. The excipient system must remain stable in the selected syringe and delivery device.

What FDA regulatory status and Orange Book issues affect metaraminol?

Metaraminol bitartrate is an old small-molecule injectable rather than a modern proprietary drug with a substantial active patent estate. FDA regulatory status must be assessed product by product because historical availability, current marketing status, and application status can differ by manufacturer and jurisdiction.

For a U.S. launch, the sponsor must establish the applicable pathway. Potential routes include:

• An ANDA, if a suitable reference-listed drug and product-specific requirements exist.
• A 505(b)(2) application where reliance on published literature or other previously established information is appropriate.
• A full 505(b)(1) application if the sponsor cannot rely on an approved reference or sufficient prior findings.

The Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity. It should not be assumed that an old active ingredient has a current Orange Book patent barrier.[4] For metaraminol, the principal regulatory work is likely to involve product quality, sterile manufacturing, labeling, bioequivalence or bridging requirements, and clinical-use justification rather than an innovative active-ingredient patent.

What patents protect metaraminol bitartrate products?

The commercial patent position is likely to be formulation- and device-specific rather than molecule-specific. Potentially protectable subject matter includes:

• A defined concentration and pH range
• A low-oxygen or antioxidant-free formulation
• A stable prefilled syringe
• A ready-to-use infusion bag
• A particular container-closure system
• A manufacturing process that reduces degradation
• A method of preventing precipitation after dilution
• A specific dosage regimen or clinical use

Composition-of-matter protection for metaraminol bitartrate would not be expected to provide a meaningful current barrier because the active ingredient has been used clinically for decades. Any live patent analysis would require a current search across the United States, Europe, the United Kingdom, Japan, China, and other target markets.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is relevant only if an ANDA applicant challenges an Orange Book-listed patent for a reference product. If no relevant listed patent protects the target product, there may be no meaningful Paragraph IV barrier. A sponsor should distinguish:

• Orange Book-listed patents
• Unlisted formulation or process patents
• Device patents
• Trade secrets
• Regulatory exclusivity
• Manufacturing know-how

For this product, competition is more likely to arise from manufacturing economics, supply reliability, hospital contracting, and presentation quality than from an active patent cliff.

What generic entry risks exist?

Generic or multisource entry risks are high once a technically acceptable sterile product is available. The active ingredient is old, the clinical use is established, and the formulation may be relatively simple.

The main entry barriers are:

Risk category	Impact on commercial position
Sterile manufacturing capacity	Can delay launch or cause supply failures
API availability	May create batch and cost volatility
Stability failures	Can prevent approval or shorten shelf life
Container compatibility	Can force reformulation
Hospital price competition	Compresses margins
Shortage-driven demand	Creates opportunity but may be temporary
Concentration confusion	Increases medication-error scrutiny
Limited clinical differentiation	Makes contracting and supply performance decisive

A manufacturer with a qualified backup API source, validated alternate packaging, and redundant sterile filling capacity can have a stronger market position than a company with a nominally superior formulation but fragile supply.

Which commercial opportunities are most attractive?

Opportunity ranking

Product concept	Market attractiveness	Development complexity	Differentiation
Preservative-free prefilled syringe	High	Medium	High
Ready-to-use infusion bag	High	High	High
Standard single-dose vial	Medium	Low	Low
Ampoule	Low to medium	Low	Low
Hospital-compounded concentrate	Low	Medium	Limited
Dual-concentration portfolio	Medium to high	Medium	Medium

The strongest initial strategy is a preservative-free, unit-dose syringe supported by a vial or infusion-bag SKU. This creates a hospital-convenience product while preserving flexibility for institutions that prefer pharmacy-controlled dilution.

How does metaraminol compare with competing vasopressors?

Metaraminol competes with phenylephrine, ephedrine, norepinephrine, and vasopressin in different clinical settings. Product selection is influenced by pharmacology, onset, duration, route, institutional protocol, and supply availability.

Drug	Typical commercial positioning	Excipient and presentation opportunity
Metaraminol	Short-term blood-pressure support, especially perioperative use	Ready-to-use syringe and standardized diluted presentations
Phenylephrine	Common perioperative vasopressor	Strong competition; differentiation must focus on workflow or supply
Ephedrine	Mixed direct and indirect sympathomimetic activity	Different clinical profile; limited direct formulation substitution
Norepinephrine	ICU and severe hypotension use	Infusion-ready bags and premixed products dominate
Vasopressin	Vasodilatory shock and selected critical-care uses	Different mechanism and formulation requirements

Metaraminol should not be positioned as a universal substitute. Its commercial value is strongest in settings where rapid, protocolized treatment of perioperative hypotension is required and where a simple unit-dose product reduces preparation time.

What licensing and partnership models are available?

The most practical transaction structures are:

1. Licensing a sterile injectable platform from a contract development and manufacturing organization.
2. Acquiring or licensing a regional metaraminol marketing authorization.
3. Establishing a supply agreement with a qualified API manufacturer.
4. Co-developing a prefilled syringe with a device or injectable specialist.
5. Using a hospital-focused commercial partner with anesthesia and critical-care contracting access.

A licensing agreement should address formulation ownership, process validation data, stability data, regulatory filing rights, API change control, alternate manufacturing sites, technology-transfer obligations, and shortage allocation. For an old generic injectable, manufacturing continuity may have greater transaction value than a narrow formulation patent.

What is the likely revenue exposure?

Revenue depends on market size, hospital tender access, supply continuity, and product presentation. The addressable opportunity is usually smaller than for major chronic-use drugs but can support attractive pricing during supply shortages or when a ready-to-use product reduces pharmacy labor.

The commercial model should separate:

• Baseline tender volume
• Shortage-driven volume
• Premium ready-to-use volume
• Private-label or contract-manufactured volume
• Regional hospital and ambulatory surgery demand
• Emergency stock and government procurement

A premium syringe or infusion bag can command higher gross profit than a conventional vial, but only if the product has validated shelf life, reliable supply, and a concentration that fits established clinical protocols.

Key Takeaways

• Metaraminol bitartrate is best approached as a sterile injectable and hospital-workflow opportunity, not as a novel-molecule patent opportunity.
• The preferred formulation is a minimal-excipient aqueous solution with tightly controlled pH, osmolality, oxygen exposure, and particulate levels.
• Preservative-free prefilled syringes offer the clearest differentiation.
• Ready-to-use infusion bags have strong commercial potential but require more extensive compatibility and in-use stability work.
• Antioxidants and chelators should be data-driven rather than automatic formulation components.
• Current competitive barriers are likely to arise from sterile manufacturing, API supply, packaging compatibility, regulatory execution, and hospital contracting.
• Orange Book and Paragraph IV risk should be assessed against the specific U.S. reference product and application pathway.
• A dual portfolio of prefilled syringes and single-dose vials provides the best balance between differentiation and market access.

FAQs

Is metaraminol bitartrate suitable for a preservative-free injection?

Yes. A single-dose, preservative-free aqueous injection is commercially appropriate when sterility, container integrity, and in-use handling are controlled.

Can metaraminol bitartrate be supplied in a prefilled syringe?

Yes. A prefilled syringe is a commercially attractive presentation, but it requires dedicated studies for syringe materials, silicone oil, plunger compatibility, extractables, leachables, particulate matter, and shelf life.

Is an antioxidant required in metaraminol bitartrate injection?

Not automatically. The need should be established through forced-degradation, oxygen-exposure, trace-metal, and container-closure studies.

Does metaraminol bitartrate have biosimilar competition?

No. Metaraminol bitartrate is a small-molecule drug. Competitive products are generics or multisource injectable products, not biosimilars.

What is the most defensible intellectual-property position for a new metaraminol product?

The strongest potential protection would likely relate to a specific stable formulation, ready-to-use presentation, container system, dilution protocol, or manufacturing process. The active ingredient itself is not a realistic source of new composition-of-matter exclusivity.

References

1. DailyMed. (n.d.). Metaraminol bitartrate injection prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
3. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210-211.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters for sterile preparations, injections, particulate matter, and packaging.-vesm